Survivin is an antiapoptotic protein expressed in tumor cells that correlates with aggressiveness, prognosis and treatment. Objective: This review summarizes significance of survivin expression among different tumor types highlighting the potential value of survivin as an important biomarker that may have an impact on patient’s response to therapy with prognostic implications.
References
[1]
Altieri, D.C. (1994) Splicing of Effector Cell Protease Receptor-1 mRNA Is Modulated by an Unusual Retained Intron. Biochemistry, 33, 13848-13855.
https://doi.org/10.1021/bi00250a039
[2]
Cohen, C., Lohmann, C.M., Cotsonis, G., Lawson, D. and Santoianni, R. (2003) (ASCP) Survivin Expression in Ovarian Carcinoma: Correlation with Apoptotic Markers and Prognosis. Modern Pathology, 16, 574-583.
https://doi.org/10.1097/01.MP.0000073868.31297.B0
[3]
Wheatley, S.P. and McNeish, I.A. (2005) Survivin: A Protein with Dual Roles in Mitosis and Apoptosis. International Review of Cytology, 247, 35-88.
https://doi.org/10.1016/S0074-7696(05)47002-3
[4]
Thornberry, N.A. and Lazebnik, Y. (1998) Caspases: Enemies within. Science, 281, 1312-1316. https://doi.org/10.1126/science.281.5381.1312
[5]
Sollberger, G., Strittmatter, G.E., Garstkiewicz, M., Sand, J. and Beer, H.-D. (2014) Caspase-1: The Inflammasome and Beyond. Innate Immunity, 20, 115-125.
https://doi.org/10.1177/1753425913484374
[6]
Altieri, D.C. (2003) Survivin, Versatile Modulation of Cell Division and Apoptosis in Cancer. Oncogene, 22, 8581-8589. https://doi.org/10.1038/sj.onc.1207113
[7]
Wang, Z., Fukuda, S. and Pelus, L.M. (2004) Survivin Regulates the p53 Tumor Suppressor Gene Family. Oncogene, 23, 8146-8153.
https://doi.org/10.1038/sj.onc.1207992
[8]
Sah, N.K., Khan, Z., Khan, G.J. and Bisen, P.S. (2006) Structural, Functional and Therapeutic Biology of Survivin. Cancer Letters, 244, 164-171.
https://doi.org/10.1016/j.canlet.2006.03.007
[9]
Fortugno, P., Wall, N.R., Giodini, A., O’Connor, D.S., Plescia, J., et al. (2002) Survivin Exists in Immunochemically Distinct Subcellular Pools and Is Involved in Spindle Microtubule Function. Journal of Cell Science, 115, 575-585.
[10]
Li, F. and Ling, X. (2006) Survivin Study: An Update of “What Is the Next Wave”? Journal of Cellular Physiology, 208, 476-486. https://doi.org/10.1002/jcp.20634
[11]
Yin, W., Chen, N., Zhang, Y., et al. (2006) Survivin Nuclear Labeling Index: A Superior Biomarker in Superficial Urothelial Carcinoma of Human Urinary Bladder. Modern Pathology, 19, 1487-1497. https://doi.org/10.1038/modpathol.3800675
[12]
Yildirim, U., Erdem, H., Kayikci, A., Sahin, A.F., Uzunlar, A.K. and Albayrak, A. (2010) Cyclooxygenase-2 and Survivin in Superficial Urothelial Carcinoma of the Bladder and Correlation with Intratumoural Microvessel Density. Journal of International Medical Research, 38, 1689-1699.
https://doi.org/10.1177/147323001003800514
[13]
Margulis, V., Lotan, Y. and Shariat, S. (2008) Survivin: A Promising Biomarker for Detection and Prognosis of Bladder Cancer. World Journal of Urology, 26, 59-65.
https://doi.org/10.1007/s00345-007-0219-y
[14]
Jeon, C., Kim, M., Kwak, C., Kim, H.H. and Ku, J.H. (2013) Prognostic Role of Survivin in Bladder Cancer: A Systematic Review and Meta-Analysis. PLoS One, 8, e76719.
https://doi.org/10.1371/journal.pone.0076719
[15]
Vriesema, J.L., Poucki, M.H., Kiemeney, L.A. and Witjes, J.A. (2000) Patient Opinion of Urinary Tests versus Flexible Urethra Cystoscopy in Follow-Up Examination for Superficial Bladder Cancer: A Utility Analysis. Urology, 56, 793-797.
https://doi.org/10.1016/S0090-4295(00)00777-9
[16]
Li, Y., Ma, X., Wu, X., Liu, X. and Liu, L. (2014) Prognostic Significance of Survivin in Breast Cancer: Meta-Analysis. The Breast Journal, 20, 514-524.
https://doi.org/10.1111/tbj.12303
[17]
Jha, K., Shukla, M. and Pandey, M. (2012) Survivin Expression and Targeting in Breast Cancer. Surgical Oncology, 21, 125-131.
https://doi.org/10.1016/j.suronc.2011.01.001
[18]
Youssef, N.S., Hewedi, I.H. and Abd Raboh, N.M. (2008) Immunohistochemical Expression of Survivin in Breast Carcinoma: Relationship with Clinicopathological Parameters, Proliferation and Molecular Classification. Journal of the Egyptian National Cancer Institute, 20, 348-357.
[19]
Ryan, B.M., Konecny, G.E., Kahlert, S., Wang, H.J., Untch, M., Meng, G., Pegram, M.D., Podratz, K.C., Crown, J., Slamon, D.J. and Duffy, M.J. (2006) Survivin Expression in Breast Cancer Predicts Clinical Outcome and Is Associated with HER2, VEGF, Urokinase Plasminogen Activator and PAI-1. Annals of Oncology, 17, 597-604.
https://doi.org/10.1093/annonc/mdj121
[20]
Li, L., Zhang, X.L., Wang, P. and Liu, Y. (2014) Expression of Survivin in Ameloblastoma and Its Clinical Significance. Shanghai Journal of Stomatology, 23, 481-484.
[21]
Khan, Z., Tiwari, R.P., Mulherkar, R., Sah, N.K., Prasad, G., Shrivastava, B.R. and Bisen, P.S. (2009) Detection of Survivin and p53 in Human Oral Cancer: Correlation with Clinicopathologic Findings. Head Neck, 31, 1039-1048.
[22]
Uzawa, T.C.K., Shibahara, T., Yokoe, H., Noma, H. and Tanzawa, H. (2003) Expression of an Inhibitor of Apoptosis, Survivin, in Oral Carcinogenesis. Journal of Dental Research, 82, 607-611. https://doi.org/10.1177/154405910308200807
[23]
Engels, K., Knauer, S.K., Metzler, D., Simf, C., Struschka, O., Bier, C., Mann, W., Kovács, A.F. and Stauber, R.H. (2007) Dynamic Intracellular Survivin in Oral Squamous Cell Carcinoma: Underlying Molecular Mechanism and Potential as an Early Prognostic Marker. The Journal of Pathology, 211, 532-540.
[24]
Lo Muzio, L., Pannone, G., Staibano, S., Mignogna, M.D., Rubini, C., Mariggiò, M.A., Procaccini, M., Ferrari, F., De Rosa, G. and Altieri, D.C. (2003) Survivin Expression in Oral Squamous Cell Carcinoma. British Journal of Cancer, 89, 2244-2248.
[25]
Su, L., Wang, Y., Xiao, M., Lin, Y. and Yu, L. (2010) Up-Regulation of Survivin in Oral Squamous Cell Carcinoma Correlates with Poor Prognosis and Chemoresistance. Oral and Maxillofacial Pathology, 110, 484-491.
[26]
Kawasaki, H., Toyoda, M., Okuda, H.S.J., Watanabe, I., et al. (2001) Expression of Survivin Correlates with Apoptosis, Proliferation, and Angiogenesis during Human Colorectal Tumorigenesis. American Cancer Society, 91, 2026-2032.
[27]
Kim, P.J., Plescia, J., Clevers, H., Fearon, E.R. and Altieri, D.C. (2003) Survivin and Molecular Pathogenesis of Colorectal Cancer. The Lancet, 362, 205-209.
[28]
Sarelaa, A.I., Macadama, R.C., Farmerya, S.M., Markhamb, A.F. and Guilloua, P.J. (2000) Expression of the Antiapoptosis Gene, Survivin, Predicts Death from Recurrent Colorectal Carcinoma. Gut, 46, 645-650. https://doi.org/10.1136/gut.46.5.645
[29]
Tu, S.P., Cui, J.T., Liston, P., et al. (2004) Gene Therapy for Colon Cancer by Adeno-Associated Viral Vector-Mediated Transfer of Survivin Cys84Ala Mutant. Gastroenterology, 128, 361-375.
[30]
Yamamotoa, T., Manomeb, Y., Nakamuraa, M. and Tanigawaa, N. (2002) Downregulation of Survivin Expression by Induction of the Effector Cell Protease Receptor-1 Reduces Tumor Growth Potential and Results in an Increased Sensitivity to Anticancer Agents in Human Colon Cancer. European Journal of Cancer, 38, 2316-2324.
[31]
Kawasaki, H., Altieri, D.C., Lu, C.-D., Toyoda, M., Tenjo, T. and Tanigawa, N. (1998) Inhibition of Apoptosis by Survivin Predicts Shorter Survival Rates in Colorectal Cancer. Cancer Research, 58, 5071-5074.
[32]
Liguang, Z., Peishu, L., Hongluan, M., Hong, J., Rong, W., Wachtel, M.S. and Frezza, E.E. (2007) Survivin Expression in Ovarian Cancer. Experimental Oncology, 29, 121-125.
[33]
Chen, L., Liang, L., Yan, X., Liu, N., Gong, L., Pan, S., Lin, F., Zhang, Q., Zhao, H. and Zheng, F. (2013) Survivin Status Affects Prognosis and Chemosensitivity in Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 23, 256-263.
https://doi.org/10.1097/IGC.0b013e31827ad2b8
[34]
Pallares, J., Martínez-Guitarte, J.L., Dolcet, X., Llobet, D., Rue, M., Palacios, J., Prat, J. and Matias-Guiu, X. (2005) Survivin Expression in Endometrial Carcinoma: A Tissue Microarray Study with Correlation with PTEN and STAT-3. International Journal of Gynecological Pathology, 24, 247-253
[35]
Vanderstraeten, A., Everaert, T., Van Bree, R., et al. (2015) In Vitro Validation of Survivin as Target Tumor-Associated Antigen for Immunotherapy in Uterine Cancer. Journal of Immunotherapy, 38, 239-249.
[36]
Congmin, G., Mu, Z., Yihui, M. and Hanliang, L. (2006) Survivin—An Attractive Target for RNAi in Non-Hodgkin’s Lymphoma, Daudi Cell Line as a Model. Leukemia & Lymphoma, 47, 1941-1948. https://doi.org/10.1080/10428190600725354
[37]
He, C., Liu, Z., Ji, J. and Zhu, H. (2015) Prognostic Value of Survivin in Patients with Non-Hodgkin’s Lymphoma: A Meta-Analysis. International Journal of Clinical and Experimental Medicine, 8, 5847-5854.
[38]
Xie, Y., Ma, X., Gu, L., Li, H., Chen, L., et al. (2016) Prognostic and Clinicopathological Significance of Survivin Expression in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Scientific Reports, 6, Article No. 29794.
[39]
Fields, A.C., Cotsonis, G., Sexton, D., Santoianni, R. and Cohen, C. (2004) Survivin Expression in Hepatocellular Carcinoma: Correlation with Proliferation, Prognostic Parameters, and Outcome. Modern Pathology, 17, 1378-1385.
https://doi.org/10.1038/modpathol.3800203
[40]
Kannangai, R., Wang, J., Liu, Q.Z., Sahin, F. and Torbenson, M. (2005) Survivin Overexpression in Hepatocellular Carcinoma Is Associated with p53 Dysregulation. International Journal of Gastrointestinal Cancer, 35, 53-60.
https://doi.org/10.1385/IJGC:35:1:053
[41]
Montorsi, M., Maggioni, M., Falleni, M., Pellegrini, C., Donadon, M., Torzilli, G., Santambrogio, R., Spinelli, A., Coggi, G. and Bosari, S.H. (2007) Survivin Gene Expression in Chronic Liver Disease and Hepatocellular Carcinoma. Hepatogastroenterology, 54, 2040-2044.
[42]
Hasby, E.A. and Mokhtar, M.A. (2010) Survivin Immunohistochemical Expression in Hepatocellular Carcinoma: Correlation with Tumor Differentiation and Proliferation. Arab Journal of Gastroenterology, 11, 141-148.
[43]
Kami, K., Doi, R., Koizumi, M., Toyoda, E., Mori, T., Ito, D., Fujimoto, K., Wada, M., Miyatake, S. and Imamura, M. (2004) Survivin Expression Is a Prognostic Marker in Pancreatic Cancer Patients. Surgery, 136, 443-448.
https://doi.org/10.1016/j.surg.2004.05.023
[44]
Waligórska-Stachura, J., Jankowska, A., Wasko, R., Liebert, W., et al. (2012) Survivin Prognostic Tumor Biomarker in Human Neoplasms—Review. Ginekologia Polska, 83, 537-540.
[45]
Rödel, F., Sprenger, T., Kaina, B., Liersch, T., Rödel, C., Fulda, S. and Hehlgans, S. (2012) Survivin as a Prognostic/Predictive Marker and Molecular Target in Cancer Therapy. Current Medicinal Chemistry, 19, 3679-3688.
[46]
Rödel, F., Reichert, S., Sprenger, T., Gaipl, U.S., Mirsch, J., Liersch, T., Fulda, S. and Rödel, C. (2011) The Role of Survivin for Radiation Oncology: Moving beyond Apoptosis Inhibition. Current Medicinal Chemistry, 18, 191-199.
https://doi.org/10.2174/092986711794088362
[47]
Blanc-Brude, O.P., Mesri, M., Wall, N.R., et al. (2003) Therapeutic Targeting of the Survivin Pathway in Cancer: Initiation of Mitochondrial Apoptosis and Suppression of Tumor-Associated Angiogenesis. Clinical Cancer Research, 9, 2683-2692.
[48]
Sharma, H., Sen, S., Mathur, M., Bahadur, S. and Singh, N. (2004) Combined Evaluation of Expression of Telomerase, Survivin, and Anti-Apoptotic bcl-2 Family Members in Relation to Loss of Differentiation and Apoptosis in Human Head and Neck Cancers. Head and Neck, 26, 733-740.
[49]
Khan, Z., Khan, N., Tiwari, R.P., Patro, I.K., Prasad, G.B. and Bisen, P.S. (2010) Down-Regulation of Survivin by Oxaliplatin Diminishes Radioresistance of Head and Neck Squamous Carcinoma Cells. Radiotherapy and Oncology, 96, 267-273.
https://doi.org/10.1016/j.radonc.2010.06.005
